SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-17-018561
Filing Date
2017-11-07
Accepted
2017-11-07 17:29:37
Documents
46
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q avir20170930_10q.htm 10-Q 467765
2 EXHIBIT 31.1 ex_98260.htm EX-31.1 16664
3 EXHIBIT 31.2 ex_98261.htm EX-31.2 16788
4 EXHIBIT 32.1 ex_98262.htm EX-32.1 13251
  Complete submission text file 0001437749-17-018561.txt   2361619

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT avir-20170930.xml EX-101.INS 413070
6 XBRL TAXONOMY EXTENSION SCHEMA avir-20170930.xsd EX-101.SCH 32204
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE avir-20170930_cal.xml EX-101.CAL 25892
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE avir-20170930_def.xml EX-101.DEF 182098
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20170930_lab.xml EX-101.LAB 146260
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20170930_pre.xml EX-101.PRE 196681
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-35285 | Film No.: 171184513
SIC: 2836 Biological Products, (No Diagnostic Substances)